• 1
    Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003; 124: 634641.
  • 2
    Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25: 135144.
  • 3
    Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 18391847.
  • 4
    Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 17011707.
  • 5
    Salerno F, Merli Manuela M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. HEPATOLOGY 2004; 40: 629635.
  • 6
    Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170178.
  • 7
    Arguedas MR, DeLawrence TG, McGuire MB. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 16221626.
  • 8
    Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of liver disease. Am J Gastroenterol 2001; 96: 21992205.
    Direct Link:
  • 9
    Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231238.
  • 10
    Zhuang ZW, Ten GJ, Jeffery RF, Gemery JM, d'Othee BJ, Bettmann MA. Long-term results and quality of life in patients treated with transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol 2002; 179: 15971603.
  • 11
    Gulberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002; 66: 127130.
  • 12
    Nazarian GK, Ferral H, Bjarnason H, Castaneda-Zuniga WR, Rank JM, Bernadas CA, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. AJR Am J Roenteneol 1996; 167: 963969.
  • 13
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996; 23: 164176.
  • 14
    Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, 1994.
  • 15
    Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chroni liver disease. Am J Gastroenterol 2001; 96: 579583.
    Direct Link:
  • 16
    van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, et al. The liver disease symptom index 2.0; validation of a disease-specific questionnaire. Qual Life Res 2004; 13: 14691481.
  • 17
    Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA. Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clinic Proceedings 2002; 77: 561571.
  • 18
    Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Heath-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630638.
    Direct Link:
  • 19
    Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 2004; 49: 453458.